J&J Stock Eyes Worst Day Since April 2025 On MedTech Miss - Johnson & Johnson (NYSE:JNJ), State Street He
Johnson & Johnson (JNJ) reported earnings beating estimates and raised its full-year forecast, but shares fell 6% due to weaker-than-expected MedTech sales. The stock is on track for its worst day since April 2025. CFO Joe Wolk noted strong fundamentals in MedTech and mentioned two new drug deals will reduce 2027 earnings by $1.36 per share.
How this was made
The 30-second read
Why it matters
The disclosed MedTech sales miss and the quantified 2027 adjusted earnings reduction from new drug deals are likely to dominate near-term positioning, even with the guidance raise.
Market read
A guidance raise is being offset by segment underperformance and a quantified future earnings drag, aligning with the stock’s sharp intraday decline.
What to watch
Traders may focus more on the magnitude and timing of the 2027 adjusted earnings reduction from the two deals, and less on the near-term MedTech revenue shortfall.
Background
The piece frames J&J as having a profit beat and higher full-year forecast, yet still tracking toward its worst day since April 2025 due to MedTech weakness.
Ticker impact
Johnson & Johnson beat profit estimates, raised its full-year forecast, but MedTech sales missed expectations and CFO said two drug deals will cut 2027 adjusted earnings by $1.36/share combined.
Likely choppy to slightly negative near term as traders weigh the guidance raise against the MedTech miss and the stated 2027 adjusted earnings headwind.
The article ties the immediate weakness to a MedTech revenue miss and quantifies a future earnings impact from Firefly Bio and Sail Biomedicines, even while reporting a profit beat and higher full-year forecast.
Market effects
Large-cap healthcare investors may reprice medtech demand sensitivity within diversified pharma-medtech models.
US large-cap defensive rotation could be tempered if medtech segment misses become a broader read-across.
Limited direct global spillover beyond healthcare medtech sentiment, absent new regulatory or geopolitical catalysts.
Counterpoint
The MedTech fundamentals are described as strong, so the market may be overreacting to a single-quarter sales miss versus the raised full-year outlook.
Key entities
- companyJohnson & Johnson
Beat profit estimates, raised full-year forecast, but MedTech sales missed and new drug deals imply a 2027 adjusted earnings headwind.
- etfState Street Health Care Select Sector SPDR ETF
XLV is mentioned as falling 1.1%, indicating broader healthcare ETF weakness alongside J&J.
